CA2812891A1 - Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome - Google Patents

Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome Download PDF

Info

Publication number
CA2812891A1
CA2812891A1 CA2812891A CA2812891A CA2812891A1 CA 2812891 A1 CA2812891 A1 CA 2812891A1 CA 2812891 A CA2812891 A CA 2812891A CA 2812891 A CA2812891 A CA 2812891A CA 2812891 A1 CA2812891 A1 CA 2812891A1
Authority
CA
Canada
Prior art keywords
mexiprostil
ibs
treatment
compound
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2812891A
Other languages
English (en)
French (fr)
Inventor
Alessandro Assandri
Luigi Moro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cosmo Technologies Ltd
Original Assignee
Cosmo Technologies Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cosmo Technologies Ltd filed Critical Cosmo Technologies Ltd
Publication of CA2812891A1 publication Critical patent/CA2812891A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CA2812891A 2010-10-19 2011-10-18 Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome Abandoned CA2812891A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI2010A001908 2010-10-19
ITMI2010A001908A IT1402047B1 (it) 2010-10-19 2010-10-19 Uso del mexiprostil nel trattamento delle malattie infiammatorie intestinali
PCT/IB2011/054627 WO2012052918A1 (en) 2010-10-19 2011-10-18 Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome

Publications (1)

Publication Number Publication Date
CA2812891A1 true CA2812891A1 (en) 2012-04-26

Family

ID=43738034

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2812891A Abandoned CA2812891A1 (en) 2010-10-19 2011-10-18 Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome

Country Status (9)

Country Link
US (1) US20130202704A1 (enExample)
EP (1) EP2629778B1 (enExample)
JP (1) JP5885749B2 (enExample)
KR (1) KR20140008306A (enExample)
CN (1) CN103167874A (enExample)
BR (1) BR112013009185A2 (enExample)
CA (1) CA2812891A1 (enExample)
IT (1) IT1402047B1 (enExample)
WO (1) WO2012052918A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
AU2011248587A1 (en) * 2011-11-09 2013-05-23 Cosmo Technologies Ltd Controlled release and taste masking oral pharmaceutical composition
CN104379140A (zh) * 2012-04-23 2015-02-25 苏坎波公司 用于治疗具有腹泻的肠易激综合征的方法
EP3291818B1 (en) * 2015-05-04 2019-10-30 The Board of Trustees of the Leland Stanford Junior University Compositions and methods for delivering therapeutic agents into the colon

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
DE3704825A1 (de) * 1987-02-16 1988-08-25 Froelich Juergen Prostaglandin e1-derivate als pharmazeutische wirkstoffe und diese verbindungen enthaltende arzneimittel insbesondere zur transkutanen anwendung
ATE82748T1 (de) * 1988-01-28 1992-12-15 Merrell Dow Pharma Verfahren und zwischenprodukte.
US6632451B2 (en) * 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
RU2246293C2 (ru) * 1999-06-14 2005-02-20 Космо С.П.А. Фармацевтические композиции для перорального введения с регулируемым высвобождением активного ингредиента и маскируемым вкусом
ITMI991316A1 (it) * 1999-06-14 2000-12-14 Cip Ninety Two 92 S A Composizioni farmaceutiche orali a rilascio modificato di mesalazina
DE60001623T2 (de) * 1999-12-03 2003-12-18 Pfizer Products Inc., Groton Sulfamoylheteroarylpyrazolverbindungen zur Verwendung als analgetisches/entzündungshemmendes Mittel
US20050159485A1 (en) * 2002-01-04 2005-07-21 Jost-Price Edward R. Combinations for the treatment of immunoinflammatory disorders and proliferative skin diseases
WO2004060377A1 (en) * 2002-12-27 2004-07-22 Sucampo Ag Derivatives of prostaglandins for treating abdominal discomfort
ATE435853T1 (de) * 2004-07-02 2009-07-15 Allergan Inc Prostaglandinanaloga

Also Published As

Publication number Publication date
US20130202704A1 (en) 2013-08-08
BR112013009185A2 (pt) 2016-07-26
KR20140008306A (ko) 2014-01-21
JP5885749B2 (ja) 2016-03-15
ITMI20101908A1 (it) 2012-04-20
WO2012052918A1 (en) 2012-04-26
IT1402047B1 (it) 2013-08-28
JP2013544795A (ja) 2013-12-19
EP2629778A1 (en) 2013-08-28
CN103167874A (zh) 2013-06-19
EP2629778B1 (en) 2016-09-21

Similar Documents

Publication Publication Date Title
JP2509044B2 (ja) 胆汁酸塩を含有する胃液耐性のある経口投与用製剤
JP3550091B2 (ja) フマル酸マイクロ錠剤
JP2002504112A (ja) 上部胃腸管の安全性を高めるためのフィルムコーティング錠
EP2629778B1 (en) Use of mexiprostil in the treatment of inflammatory bowel disease and/or of irritable bowel syndrome
JP2991733B2 (ja) 乾癬疾患を抑制するための薬剤及びその製法
JP2002513418A (ja) 治療活性組成物
TW201442712A (zh) 有機化合物之調配物
JP4634713B2 (ja) ヘパリン又はその誘導体の経口的投与のための製薬学的組成物
JPH02268178A (ja) ３―ホルミルアミノ―７―メチルスルホニルアミノ―６―フェノキシ―４ｈ―１―ベンゾピラン―４―オンまたはその塩を含有する抗炎症製剤
JP2003517443A (ja) 炎症性腸疾患を治療するための方法および組成物
RU2341529C2 (ru) Гликозидное пролекарство 5-аминосалициловой кислоты
AU2006226381B2 (en) Use of macrolides for treating intestinal inflammation
EP1751145A1 (en) Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or cholic acid derivatives
US11858908B2 (en) Compositions and methods for inhibiting IDO1
JP6407974B2 (ja) 炎症性腸疾患の処置のためのチアゾロピリミジノンの使用
US20250270205A1 (en) Compositions and methods for inhibiting trem-1
WO2023002338A1 (en) Compositions, methods of making and using same for the delivery of ulcerogenic drugs thereof
US9308220B2 (en) Pharmaceutical compositions for the oral administration of heparin or derivatives thereof
EP4251629A1 (en) Compositions and methods for inhibiting fibrosis, inflammation and cancer
WO2021236891A1 (en) Gut-targeted phosphodiesterase inhibitors
JPH0558885A (ja) 抗潰瘍剤
CN112641747A (zh) 一种高纯度美沙拉嗪肠溶缓释片制剂及其制备方法
Klotz Pharmacological Development of Aminosalicylates for the Treatment of Inflammatory Bowel Disease

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20171018